Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.38 |
| ▸ | FNTB | P49356 | 5/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7867254 | 0.90 | FNTA (0.35) | FNTAFNTBPGGT1B | |
| SCHEMBL7570953 | 0.88 | FNTA (0.41) | FNTAFNTBMAPK1 | |
| SCHEMBL7563326 | 0.84 | FNTA (0.52) | FNTAFNTB | |
| SCHEMBL7565353 | 0.83 | FNTA (0.33) | FNTAFNTBMAPK1 | |
| SCHEMBL7862118 | 0.81 | ITGB1 (0.33) | FNTAFNTBITGB1ITGA4ITGB7 | |
| SCHEMBL7564340 | 0.81 | NAMPT (0.36) | FNTAFNTBPGGT1BMAPK1 | |
| SCHEMBL7564177 | 0.78 | FNTA (0.38) | FNTAFNTB | |
| SCHEMBL7863509 | 0.75 | PTGS2 (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL7864932 | 0.75 | CAPN1 (0.36) | FNTAFNTBPGGT1BMAPK1 | |
| SCHEMBL8185757 | 0.75 | FNTA (0.33) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | FNTA 1/4885FNTB 2/4885PGGT1B 39/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | FNTA 1/4885FNTB 2/4885PGGT1B 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.